ONCT News and Press, Oncternal Therapeutics Inc. From 03/11/21

Interim Phase 1/2 results for cirmtuzumab with ibrutinib in MCL presented at ASH in December 2020 compare favorably to historical single-agent ibrutinib data (47% CR vs. 20% CR historical single-agent ibrutinib) Accelerating development of ROR1-targeting CAR-T cell therapies ...

SAN DIEGO, March 04, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2020 financial results after the U.S...

- H.C. Wainwright: Global Life Sciences Conference - March 9 th – 10 th - Oppenheimer 31 st Annual Healthcare Conference - March 16 th – 17 th SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a cl...

SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted an inducement award to one new non-executive employee, Christy Sto...

Oncternal is one of the oldest companies in the ROR1 oncology space, a field fraught with recent acquisitions. Almost every other player in the ROR1 space has been scooped up by big pharma players, but mostly those in ADCs. To understand the different approaches in this niche of o...

Oncternal has solid data for cirmtuzumab+ibrutinib in MCL and CLL. It has cash it says is enough for 2 years. If successful, this could be a good stock to own. For further details see: Oncternal: Solid Data In Tough-To-Treat Cancer

Oncternal has potential winner with cirmtuzumab in mantle cell lymphoma. A potential pediatric review voucher for TK216 in Ewing sarcoma alone is worth $80-150 million. Their current valuation sets a possibility for significant upside. For further details see: Oncternal ...

SAN DIEGO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Rosemary Mazanet, M.D., Ph.D., to its Board of Directors, effective...

Oncternal Therapeutics (ONCT) announces agreement with Lentigen Technology, a wholly-owned subsidiary of Miltenyi Biotec B.V. & Co. KG, to manufacture lentiviral vectors for Oncternal’s investigational ROR1-targeting CAR-T cell therapy program.As part of the agreement, Lentigen wil...

SAN DIEGO, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced an agreement with Lentigen Technology, Inc. (“Lentigen”), a wholly-owned...